{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:42:37Z","timestamp":1791502957984,"version":"4.3.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["179571"],"award-info":[{"award-number":["179571"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Zurich's Clinical Research Priority Program's"},{"name":"ZPHI"},{"DOI":"10.13039\/100008367","name":"SNF","doi-asserted-by":"publisher","award":["PZ00P3-142411"],"award-info":[{"award-number":["PZ00P3-142411"]}],"id":[{"id":"10.13039\/100008367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008367","name":"SNF","doi-asserted-by":"publisher","award":["BSSGI0_155851"],"award-info":[{"award-number":["BSSGI0_155851"]}],"id":[{"id":"10.13039\/100008367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Starting combination antiretroviral therapy (cART) during primary human immunodeficiency virus type 1 (HIV-1) infection results in a smaller HIV-1 latent reservoir, reduced immune activation, and less viral diversity compared to starting cART during chronic infection. We report results of a 4-year study designed to determine whether these properties would allow sustained virological suppression after simplification of cART to dolutegravir (DTG) monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>EARLY-SIMPLIFIED is a randomized, open-label, noninferiority trial. People with HIV (PWH) who started cART &amp;lt;180 days after a documented primary HIV-1 infection with suppressed viral load were randomized (2:1) to DTG monotherapy with 50 mg daily or continuation of cART. The primary endpoints were the proportion of PWH with viral failure at 48, 96, 144, and 192 weeks; noninferiority margin was 10%. After 96 weeks, randomization was lifted and patients were permitted to switch treatment groups as desired.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 101 PWH randomized, 68 were assigned to DTG monotherapy and 33 to cART. At week 96 in the per-protocol population, 64\/64 (100%) showed virological response in the DTG monotherapy group versus 30\/30 (100%) in the cART group (difference, 0.00%; upper bound of 95% confidence interval 6.22%). This demonstrated noninferiority of DTG monotherapy at the prespecified level. At week 192, the study end, no virological failure occurred in either group during 13 308 and 4897 person weeks of follow-up for the DTG monotherapy (n = 80) and cART groups, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This trial suggests that early cART initiation during primary HIV infection allows sustained virological suppression after switching to DTG monotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad366","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T12:16:21Z","timestamp":1687263381000},"page":"1012-1020","source":"Crossref","is-referenced-by-count":14,"title":["Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial"],"prefix":"10.1093","volume":"77","author":[{"given":"Emily","family":"West","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6822-1473","authenticated-orcid":false,"given":"Marius","family":"Zeeb","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Grube","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Kuster","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Wanner","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Scheier","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Neumann","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"J\u00f6rimann","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"},{"name":"Institute of Medical Virology, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hampel","sequence":"additional","affiliation":[{"name":"Checkpoint Zurich , Zurich , Switzerland"},{"name":"Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin J","family":"Metzner","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"},{"name":"Institute of Medical Virology, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9220-8348","authenticated-orcid":false,"given":"Roger D","family":"Kouyos","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"},{"name":"Institute of Medical Virology, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique L","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"},{"name":"Institute of Medical Virology, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huldrych F","family":"G\u00fcnthard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich , Switzerland"},{"name":"Institute of Medical Virology, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"2024021206393678900_ciad366-B1","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/135965350701200808","article-title":"Adverse events to antiretrovirals in the Swiss HIV cohort study: effect on mortality and treatment modification","volume":"12","author":"Keiser","year":"2007","journal-title":"Antivir Ther"},{"key":"2024021206393678900_ciad366-B2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024021206393678900_ciad366-B3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101116","article-title":"Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)","volume":"40","author":"Bischoff","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2024021206393678900_ciad366-B4","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac538","article-title":"Factors associated with liver steatosis in people with human immunodeficiency virus on contemporary antiretroviral therapy","volume":"9","author":"Riebensahm","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024021206393678900_ciad366-B5"},{"key":"2024021206393678900_ciad366-B6","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024021206393678900_ciad366-B7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-Acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2024021206393678900_ciad366-B8","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"2024021206393678900_ciad366-B9","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024021206393678900_ciad366-B10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/cid\/ciy1132","article-title":"Dolutegravir monotherapy versus dolutegravir\/Abacavir\/lamivudine for virologically suppressed people living with chronic human immunodeficiency virus infection: the randomized noninferiority MONotherapy of TiviCAY trial","volume":"69","author":"Hocqueloux","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024021206393678900_ciad366-B11","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac107","article-title":"Dolutegravir monotherapy as maintenance strategy: a meta-analysis of individual participant data from randomized controlled trials","volume":"9","author":"Fournier","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024021206393678900_ciad366-B12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/ciy1131","article-title":"Noninferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary human immunodeficiency virus infection: a randomized, controlled, multisite, open-label, noninferiority trial","volume":"69","author":"Braun","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024021206393678900_ciad366-B13","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/cid\/cir725","article-title":"Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection","volume":"53","author":"Rieder","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2024021206393678900_ciad366-B14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ije\/dyab141","article-title":"Cohort profile update: the Swiss HIV Cohort Study (SHCS)","volume":"51","author":"Scherrer","year":"2022","journal-title":"Int J Epidemiol"},{"key":"2024021206393678900_ciad366-B15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/cid\/cix873","article-title":"High rates of subsequent asymptomatic sexually transmitted infections and risky sexual behavior in patients initially presenting with primary human immunodeficiency virus-1 infection","volume":"66","author":"Braun","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024021206393678900_ciad366-B16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.1993.03500060023008","article-title":"1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"269","author":"From the Centers for Disease Control and Prevention","year":"1993","journal-title":"JAMA"},{"key":"2024021206393678900_ciad366-B17","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1038\/s41467-019-10884-9","article-title":"Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART","volume":"10","author":"Bachmann","year":"2019","journal-title":"Nat Commun"},{"key":"2024021206393678900_ciad366-B18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.32614\/RJ-2013-026","article-title":"ExactCIdiff: an R package for computing exact confidence intervals for the difference of two proportions.","volume":"5","author":"Shan","year":"2013","journal-title":"R Journal"},{"key":"2024021206393678900_ciad366-B19","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2024021206393678900_ciad366-B20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2024021206393678900_ciad366-B21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/hiv.13268","article-title":"Major revision version 11.0 of the European AIDS Clinical Society guidelines 2021","volume":"23","author":"Ryom","year":"2022","journal-title":"HIV Med"},{"key":"2024021206393678900_ciad366-B22","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12688\/f1000research.15995.1","article-title":"Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: systematic review and meta-analysis","volume":"7","author":"Wandeler","year":"2018","journal-title":"F1000Res"},{"key":"2024021206393678900_ciad366-B23","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3018(21)00163-6","article-title":"Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium","volume":"8","author":"Bansi-Matharu","year":"2021","journal-title":"Lancet HIV"},{"key":"2024021206393678900_ciad366-B24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann Intern Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad366\/50958076\/ciad366.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/7\/1012\/56647832\/ciad366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/7\/1012\/56647832\/ciad366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T06:40:20Z","timestamp":1707720020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/7\/1012\/7203698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,20]]},"published-print":{"date-parts":[[2023,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad366","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,6,20]]}}}